{
    "organizations": [],
    "uuid": "ba3b4af214715617e4cb5e890b5f8d21b8c5cd8e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abeona-therapeutics-says-gene-ther/brief-abeona-therapeutics-says-gene-therapy-abo-101-is-well-tolerated-idUSASB0C4HI",
    "ord_in_thread": 0,
    "title": "BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 7, 2018 / 1:55 PM / in 7 minutes BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Abeona Therapeutics Inc: \n* ABEONA THERAPEUTICS REPORTS ON INITIAL SAFETY AND BIOPOTENCY SIGNALS IN MPS IIIB GENE THERAPY CLINICAL TRIAL \n* ABEONA THERAPEUTICS INC - ABO-101 IS WELL TOLERATED Source text for Eikon: Further company coverage:",
    "published": "2018-02-07T15:54:00.000+02:00",
    "crawled": "2018-02-07T16:12:35.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "therapeutic",
        "say",
        "gene",
        "therapy",
        "well",
        "tolerated",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "abeona",
        "therapeutic",
        "inc",
        "abeona",
        "therapeutic",
        "report",
        "initial",
        "safety",
        "biopotency",
        "signal",
        "mp",
        "iiib",
        "gene",
        "therapy",
        "clinical",
        "trial",
        "abeona",
        "therapeutic",
        "inc",
        "well",
        "tolerated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}